Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Fineline Cube Dec 18, 2025
Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Fineline Cube Dec 18, 2025
Company Drug

Genor Biopharma Initiates First Patient Dosing for GB263T in China

Fineline Cube Oct 17, 2022

China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced the first patient dosing in a...

Company Drug

Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study

Fineline Cube Oct 17, 2022

China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...

Company Drug

Innovent Biologics Publishes Mazdutide Phase Ib Study Results for Obesity

Fineline Cube Oct 17, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the results of the higher-dose cohorts...

Company Deals

Sihuan Pharma to Acquire Additional Stake in Heilongjiang Duoduo Pharma

Fineline Cube Oct 17, 2022

China-based Sihuan Pharmaceutical Holdings Group Ltd’s subsidiary, Beijing Centergate Technologies (Holding) Co., Ltd (SHE: 000931),...

Policy / Regulatory

NHSA Completes Expert Review for NRDL Price Negotiation Process

Fineline Cube Oct 17, 2022

The National Healthcare Security Administration (NHSA) has released a notification indicating that the expert review...

Company Drug

BeiGene’s Brukinsa Receives Positive CHMP Opinion for CLL Approval

Fineline Cube Oct 17, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving a positive opinion...

Company Drug

Kira Pharmaceuticals Gains NMPA Approval for Phase II Study of KP104 in PNH

Fineline Cube Oct 17, 2022

Sino-US biotech Kira Pharmaceuticals has announced receiving approval from the National Medical Products Administration (NMPA)...

Company Drug

RemeGen’s Telitacicept Gains EU, China Approvals for Global Phase III Study

Fineline Cube Oct 17, 2022

China-based pharma firm RemeGen (HKG: 9995) has announced receiving approvals from authorities in the European...

Company Drug

Zelgen’s Jacktinib Shows Strong Efficacy in Phase III Myelofibrosis Study

Fineline Cube Oct 17, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has published major data from a Phase III...

Company Deals

Ningbo Menovo to Sell Zhejiang Liaoyuan Pharma Stake to Jemincare for RMB 512.58M

Fineline Cube Oct 17, 2022

China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to transfer all of...

Company Deals

Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development

Fineline Cube Oct 14, 2022

Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV)...

Company Deals

Alioth Biotech Raises RMB 100M in Series A Financing for Pharma Processing Products

Fineline Cube Oct 14, 2022

China-based Alioth Biotech (Shanghai) Co., Ltd has raised close to RMB 100 million (USD 13.9...

Company Deals

HICOMP MicroTech Raises RMB 100M in Series B+ Financing for Microfluidics Expansion

Fineline Cube Oct 14, 2022

China-based micro/nano technology developer HICOMP MicroTech (Suzhou) Co., Ltd has raised RMB 100 million (USD...

Company Drug

Kintor’s Dual c-Myc/GSPT1 Degradation Therapy GT19715 Shows Promise in Pre-Clinical Studies

Fineline Cube Oct 14, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published positive results from a pre-clinical study of...

Company Drug

CARsgen’s BCMA-Targeted CAR-T Therapy CT053 Gains Priority Review in China

Fineline Cube Oct 14, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based chimeric antigen receptor (CAR)-T cell...

Company Drug

LianBio Cancels Phase III Trial for Truseltiq in China Amid Global Halt

Fineline Cube Oct 14, 2022

China-based LianBio (OTCMKTS: LIANY) revealed in an SEC filing that it is canceling work on...

Company Drug

Accutar Biotechnology Initiates Phase I Trial for ERα Targeting Degradation Molecule AC0682

Fineline Cube Oct 14, 2022

New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the...

Policy / Regulatory R&D

CDE Releases Draft Guidelines for Extrapolating Adult Drug Data to Pediatric Use

Fineline Cube Oct 14, 2022

The Center for Drug Evaluation (CDE) has released the “Guidelines on Quantitative Methodology for Extrapolating...

Company Drug

RemeGen’s Telitacicept Receives FDA Orphan Drug Designation for Myasthenia Gravis

Fineline Cube Oct 13, 2022

China-based pharma firm RemeGen (HKG: 9995, SHA: 688331) has announced receiving Orphan Drug Designation (ODD)...

Company Deals

Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study

Fineline Cube Oct 13, 2022

China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership...

Posts pagination

1 … 548 549 550 … 599

Recent updates

  • Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
  • DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer
  • Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan
  • Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets
  • Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Company Drug

Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan

Company Drug

Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.